Search results
Results from the WOW.Com Content Network
Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. [10] Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. [10] Use during pregnancy may harm foetal development. [10]
Flutamide has been researched and used extensively in the treatment of androgen-dependent skin and hair conditions in women including acne, seborrhea, hirsutism, and scalp hair loss, as well as in hyperandrogenism (e.g., in polycystic ovary syndrome or congenital adrenal hyperplasia), and is effective in improving the symptoms of these conditions.
The core side effects of NSAAs such as gynecomastia, sexual dysfunction, and hot flashes occur at similar rates with the different drugs. [ 48 ] [ 49 ] Conversely, bicalutamide is associated with a significantly lower rate of diarrhea compared to flutamide.
A few months ago, we looked into Ozempic face, a phenomenon that happens when a decrease in fat creates hollowness in the eyes, cheek area and temples, creating a more skeletal and aged appearance ...
The most common side effects from this procedure include itching, rash, nausea, facial flushing/sweating. [10] Some patients experience temporary weight gain due to the steroid. Diabetics may experience an increase in blood sugar. [10] [4] This is a quick and simple procedure, so complications are very rare, but should not be ignored. The risk ...
But some research has noted rare but serious side effects of once-weekly, 2.4-milligram (mg) semaglutide injections, such as pancreatitis, acute kidney injury, gallbladder issues, and thyroid cancer.
Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. [2] [4] It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...